本帖最后由 老马 于 2012-1-13 21:20 编辑
/ s- [7 ^3 ?" N! ]
( H" ?( Q9 f0 n# c/ d" ^& K$ l爱必妥和阿瓦斯丁的比较1 I0 Q" {/ L: Y, {
" D/ Z( N) U( z0 A, @. U9 V6 x* phttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/+ e M+ H4 W! X+ A
% b# q% G, x6 E' w S6 j
( `7 p! v; \ d& ?" v+ M
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
v+ `! s& f- ^' b T4 U" _==================================================
+ U% D5 S& F8 k, B& K3 N! h8 SOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
* Z0 w1 l/ |: A \ P6 q1 T/ ^9 F; APatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
* w+ c: U9 y& U6 N* Q0 ^Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
3 z% O$ O5 L8 i* H
|